BioTuesdays

Tag - PMCB

PharmaCyte Logo

HCW starts PharmaCyte Biotech at neutral

H.C. Wainwright initiated coverage of PharmaCyte Biotech (NASDAQ:PMCB) with a “neutral” rating without a price target, as “we await the FDA’s clinical hold to be lifted.” The stock closed at $2.93 on Oct. 5. “Once...